Bristol Myers Squibb & Co (BMY) has announced promising new data from the Phase 3 Daybreak trial, highlighting the long-term efficacy of Zeposia (ozanimod) in managing relapsing forms of multiple sclerosis (MS). The study’s open-label extension (OLE) phase, which followed patients for up to five years, demonstrated sustained reductions in brain volume loss.
The results revealed that patients who continuously received Zeposia treatment experienced low and stable rates of whole brain volume (WBV) loss through Month 60. This stability was evident in both the Radiance and Sunbeam cohorts, with annualized least squares mean (LSM) percentage changes from baseline of -0.27 and -0.35, respectively.
Adding to the positive findings, a separate safety analysis within the Daybreak OLE demonstrated a decline or stabilization in the incidence of treatment-emergent adverse events (TEAEs). Notably, the rates of infections, serious infections, and opportunistic infections remained relatively low over more than eight years of Zeposia treatment, suggesting a favorable safety profile for the drug.
These findings are particularly noteworthy because they showcase the sustained benefits of Zeposia in managing brain volume loss in MS patients. The study also highlighted the positive effect of switching from interferon beta-1a (IFN-β) treatment to Zeposia, consistently reducing rates of WBV loss. Additionally, similar reductions were observed in thalamic volume loss, a brain region crucial for sensory processing and relaying information to the cerebral cortex.
These findings will be presented at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, further solidifying Zeposia’s position as a valuable treatment option for individuals with relapsing forms of MS.
